Research Analysts Issue Forecasts for GPCR FY2025 Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Analysts at HC Wainwright decreased their FY2025 earnings per share estimates for shares of Structure Therapeutics in a research report issued on Monday, November 10th. HC Wainwright analyst A. Ghosh now forecasts that the company will earn ($1.28) per share for the year, down from their prior forecast of ($1.22). HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Structure Therapeutics’ Q4 2025 earnings at ($0.29) EPS, Q1 2026 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.20) EPS, FY2027 earnings at ($1.70) EPS, FY2028 earnings at ($1.78) EPS and FY2029 earnings at ($1.87) EPS.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01).

GPCR has been the subject of several other research reports. Lifesci Capital upgraded shares of Structure Therapeutics to a “strong-buy” rating in a research report on Monday, September 8th. Guggenheim decreased their price target on shares of Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. JMP Securities lowered their price target on shares of Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating for the company in a report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Structure Therapeutics in a research report on Tuesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $68.67.

Structure Therapeutics Stock Up 2.9%

Structure Therapeutics stock opened at $34.87 on Wednesday. The stock has a 50-day simple moving average of $26.92 and a 200 day simple moving average of $23.11. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -28.58 and a beta of -1.63. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $38.67.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. DNB Asset Management AS boosted its position in shares of Structure Therapeutics by 21.2% in the 3rd quarter. DNB Asset Management AS now owns 12,888 shares of the company’s stock worth $361,000 after purchasing an additional 2,253 shares during the last quarter. Private Capital Advisors Inc. bought a new stake in Structure Therapeutics in the third quarter valued at about $1,545,000. EverSource Wealth Advisors LLC lifted its stake in Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after buying an additional 901 shares during the period. ANTIPODES PARTNERS Ltd lifted its stake in Structure Therapeutics by 39.1% in the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after buying an additional 1,146 shares during the period. Finally, Readystate Asset Management LP boosted its holdings in Structure Therapeutics by 32.8% during the third quarter. Readystate Asset Management LP now owns 237,188 shares of the company’s stock worth $6,641,000 after buying an additional 58,576 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.